首页 > 最新文献

Pulmonary Medicine最新文献

英文 中文
Comparison of the Clinical Efficacy of Salbutamol with Jet and Mesh Nebulizers in Asthmatic Children. 沙丁胺醇与喷雾器、网状喷雾器治疗儿童哮喘的临床疗效比较。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2018-03-13 eCollection Date: 2018-01-01 DOI: 10.1155/2018/1648652
Norihide Murayama, Kikuno Murayama

Background: Ultrasonic, jet, and mesh nebulizers have all been used in the treatment for asthma. Mesh nebulizers reportedly offer the best inhalation efficiency.

Methods: This study aimed to clarify the utility of the mesh nebulizer, compared to jet nebulizers, in the treatment of pediatric asthma patients. Participants included 88 children <6 years old who were receiving treatment for asthma at Murayama Pediatric Clinic. Heart rate, peripheral oxygen saturation in arterial blood, and Mitsui symptom scores were compared before and after treatment with a mesh nebulizer (n = 43) or jet nebulizer (n = 45) using a salbutamol inhalation solution (0.2 ml for children ≧ 2 years old, n = 51; 0.1 ml for children < 2 years old, n = 37).

Results: Other than required inhalation time, clinical findings did not differ between mesh and jet groups. In both groups, heart rate increased significantly in patients treated with 0.2 ml (1000 microg) of salbutamol.

Conclusions and clinical relevance: The required inhalation time of the mesh nebulizer was superior to the jet nebulizer. Children ≧ 2 years with mild asthma attacks experienced a significantly increased heart rate in both groups. The dose of salbutamol (0.2 ml for ≧2 years) used for asthma attacks should be reconsidered in mild asthma.

背景:超声、喷射和网状喷雾器都被用于治疗哮喘。网状雾化器据说提供最好的吸入效率。方法:本研究旨在阐明网状喷雾器与喷射喷雾器在小儿哮喘患者治疗中的作用。参与者包括88名儿童(n = 43)或喷射雾化器(n = 45),使用沙丁胺醇吸入溶液(0.2 ml,≥2岁儿童,n = 51;< 2岁儿童0.1 ml, n = 37)。结果:除所需吸入时间外,补片组和喷射组的临床表现无显著差异。在两组中,使用0.2 ml(1000微克)沙丁胺醇治疗的患者心率显著增加。结论及临床意义:网状喷雾器吸入所需时间优于喷射喷雾器。≧2年轻度哮喘发作儿童两组心率均显著增高。轻度哮喘发作时应重新考虑沙丁胺醇(0.2 ml≥2年)的剂量。
{"title":"Comparison of the Clinical Efficacy of Salbutamol with Jet and Mesh Nebulizers in Asthmatic Children.","authors":"Norihide Murayama,&nbsp;Kikuno Murayama","doi":"10.1155/2018/1648652","DOIUrl":"https://doi.org/10.1155/2018/1648652","url":null,"abstract":"<p><strong>Background: </strong>Ultrasonic, jet, and mesh nebulizers have all been used in the treatment for asthma. Mesh nebulizers reportedly offer the best inhalation efficiency.</p><p><strong>Methods: </strong>This study aimed to clarify the utility of the mesh nebulizer, compared to jet nebulizers, in the treatment of pediatric asthma patients. Participants included 88 children <6 years old who were receiving treatment for asthma at Murayama Pediatric Clinic. Heart rate, peripheral oxygen saturation in arterial blood, and Mitsui symptom scores were compared before and after treatment with a mesh nebulizer (<i>n</i> = 43) or jet nebulizer (<i>n</i> = 45) using a salbutamol inhalation solution (0.2 ml for children ≧ 2 years old, <i>n</i> = 51; 0.1 ml for children < 2 years old, <i>n</i> = 37).</p><p><strong>Results: </strong>Other than required inhalation time, clinical findings did not differ between mesh and jet groups. In both groups, heart rate increased significantly in patients treated with 0.2 ml (1000 microg) of salbutamol.</p><p><strong>Conclusions and clinical relevance: </strong>The required inhalation time of the mesh nebulizer was superior to the jet nebulizer. Children ≧ 2 years with mild asthma attacks experienced a significantly increased heart rate in both groups. The dose of salbutamol (0.2 ml for ≧2 years) used for asthma attacks should be reconsidered in mild asthma.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2018 ","pages":"1648652"},"PeriodicalIF":4.3,"publicationDate":"2018-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/1648652","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36075206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension. 肺动脉高压合并毛细血管后和毛细血管前肺动脉高压患者的特异性治疗。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2018-03-01 eCollection Date: 2018-01-01 DOI: 10.1155/2018/7056360
Hassan Alfraidi, Sultan Qanash, Zoheir Bshouty

Background: Specific therapy for patients with PAH is associated with good outcomes. Little is known about the effect of this treatment in patients with Cpc-PH (PAPm ≥ 25 mmHg, PAWP > 15 mmHg, DPG ≥ 7 mmHg, and/or PVR > 3 WU). This study evaluates the outcome of treating patients with Cpc-PH using PAH specific therapy.

Methods: The primary outcome was survival. Secondary outcomes were WHO functional class and 6-minute walk distance (6-MWD).

Results: Twenty-six patients with Cpc-PH (half with VHD and half with HF) received PAHST. Six patients did not tolerate treatment due to pulmonary edema. No predictors for treatment intolerance were identified. In twenty patients who tolerated the treatment, the mean WHO functional class improved from 2.70 ± 0.21 at initial assessment to 2.22 ± 0.21 (p < 0.04) and 2.06 ± 0.21 (p < 0.03) at 6 and 9 months, respectively. Mean 6-MWD improved from 276.0 ± 38.50 meters at initial assessment to 343.9 ± 22.99 meters (p < 0.04) and 364.6 ± 34.85 meters (p = 0.07) at 6 and 9 months, respectively. Twelve patients died during the follow-up period. Mean survival for all patients was 1279.7 ± 193.60 days.

Conclusion: PAHST may be beneficial in the treatment of Cpc-PH (both short and long term). Prospective randomized controlled trials of PAHST in this population are needed to assess its potential efficacy.

背景:PAH患者的特异性治疗与良好的预后相关。对于Cpc-PH (PAPm≥25 mmHg, paap > 15 mmHg, DPG≥7 mmHg,和/或PVR > 3wu)患者,这种治疗的效果知之甚少。本研究评估了使用PAH特异性疗法治疗Cpc-PH患者的结果。方法:主要终点为生存。次要指标为WHO功能分级和6分钟步行距离(6-MWD)。结果:26例Cpc-PH患者(一半合并VHD,一半合并HF)接受了PAHST治疗。6例患者因肺水肿不能耐受治疗。未发现治疗不耐受的预测因素。在20例耐受治疗的患者中,平均who功能等级分别从最初评估时的2.70±0.21提高到6个月和9个月时的2.22±0.21 (p < 0.04)和2.06±0.21 (p < 0.03)。平均6- mwd分别从最初评估时的276.0±38.50米提高到6个月时的343.9±22.99米(p < 0.04)和9个月时的364.6±34.85米(p = 0.07)。12例患者在随访期间死亡。所有患者的平均生存期为1279.7±193.60天。结论:PAHST治疗Cpc-PH(短期和长期)均有疗效。需要在该人群中进行前瞻性随机对照试验来评估其潜在疗效。
{"title":"Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension.","authors":"Hassan Alfraidi,&nbsp;Sultan Qanash,&nbsp;Zoheir Bshouty","doi":"10.1155/2018/7056360","DOIUrl":"https://doi.org/10.1155/2018/7056360","url":null,"abstract":"<p><strong>Background: </strong>Specific therapy for patients with PAH is associated with good outcomes. Little is known about the effect of this treatment in patients with Cpc-PH (PAPm ≥ 25 mmHg, PAWP > 15 mmHg, DPG ≥ 7 mmHg, and/or PVR > 3 WU). This study evaluates the outcome of treating patients with Cpc-PH using PAH specific therapy.</p><p><strong>Methods: </strong>The primary outcome was survival. Secondary outcomes were WHO functional class and 6-minute walk distance (6-MWD).</p><p><strong>Results: </strong>Twenty-six patients with Cpc-PH (half with VHD and half with HF) received PAHST. Six patients did not tolerate treatment due to pulmonary edema. No predictors for treatment intolerance were identified. In twenty patients who tolerated the treatment, the mean WHO functional class improved from 2.70 ± 0.21 at initial assessment to 2.22 ± 0.21 (<i>p</i> < 0.04) and 2.06 ± 0.21 (<i>p</i> < 0.03) at 6 and 9 months, respectively. Mean 6-MWD improved from 276.0 ± 38.50 meters at initial assessment to 343.9 ± 22.99 meters (<i>p</i> < 0.04) and 364.6 ± 34.85 meters (<i>p</i> = 0.07) at 6 and 9 months, respectively. Twelve patients died during the follow-up period. Mean survival for all patients was 1279.7 ± 193.60 days.</p><p><strong>Conclusion: </strong>PAHST may be beneficial in the treatment of Cpc-PH (both short and long term). Prospective randomized controlled trials of PAHST in this population are needed to assess its potential efficacy.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2018 ","pages":"7056360"},"PeriodicalIF":4.3,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/7056360","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36036329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Sarcoid-Like Mediastinal Lymphadenopathy in Gynecologic Malignancy. 妇科恶性肿瘤中的结节样纵隔淋巴结病。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2018-02-14 eCollection Date: 2018-01-01 DOI: 10.1155/2018/5141575
Bilal H Lashari, Megumi Asai, Gissele Randleman, Martha Sack, Rajeshkumar Patel

Noncaseating granulomas are seen surrounding tumors with varying frequency, possibly as part of an immune response to tumor cells. However, data about the association of sarcoid with gynecologic malignancy is sparse. We performed a search of our institutional database for all EBUS-TBNA biopsies conducted within the past five years that revealed granulomatous inflammation. All adult female patients with a history of gynecologic malignancy were included. Patients with a history of sarcoidosis or fungal or mycobacterial infection were excluded. All patients with evidence of malignant cells on TBNA specimen were excluded. Our results revealed 65 patients with histologic diagnosis of a noncaseating granuloma on EBUS-TBNA. Five patients (7.69%) had a history of gynecologic malignancy. Two patients had evidence of PET-positive nodes on surveillance scans, which led directly to the examination. Our findings suggest that distant malignancies may cause granulomatous lymphadenitis, through yet undefined mechanisms. As such, patients with evidence of mediastinal lymphadenopathy could benefit from routine sampling and histologic examination to define the pathology in the correct clinical context.

肿瘤周围可见非干酪化肉芽肿,频率不同,可能是对肿瘤细胞的免疫反应的一部分。然而,关于肉瘤与妇科恶性肿瘤的关系的资料很少。我们对我们的机构数据库进行了搜索,查找过去五年内发现肉芽肿性炎症的所有ebu - tbna活检。所有有妇科恶性肿瘤病史的成年女性患者均被纳入研究。排除有结节病或真菌或分枝杆菌感染史的患者。所有TBNA标本上有恶性细胞证据的患者均被排除。我们的结果显示65例患者在EBUS-TBNA上的组织学诊断为非干酪化肉芽肿。5例(7.69%)有妇科恶性肿瘤病史。两名患者在监测扫描中有pet阳性淋巴结的证据,这直接导致了检查。我们的研究结果表明,远处恶性肿瘤可能通过尚未明确的机制引起肉芽肿性淋巴结炎。因此,有纵隔淋巴结病证据的患者可以从常规取样和组织学检查中获益,以在正确的临床背景下确定病理。
{"title":"Sarcoid-Like Mediastinal Lymphadenopathy in Gynecologic Malignancy.","authors":"Bilal H Lashari,&nbsp;Megumi Asai,&nbsp;Gissele Randleman,&nbsp;Martha Sack,&nbsp;Rajeshkumar Patel","doi":"10.1155/2018/5141575","DOIUrl":"https://doi.org/10.1155/2018/5141575","url":null,"abstract":"<p><p>Noncaseating granulomas are seen surrounding tumors with varying frequency, possibly as part of an immune response to tumor cells. However, data about the association of sarcoid with gynecologic malignancy is sparse. We performed a search of our institutional database for all EBUS-TBNA biopsies conducted within the past five years that revealed granulomatous inflammation. All adult female patients with a history of gynecologic malignancy were included. Patients with a history of sarcoidosis or fungal or mycobacterial infection were excluded. All patients with evidence of malignant cells on TBNA specimen were excluded. Our results revealed 65 patients with histologic diagnosis of a noncaseating granuloma on EBUS-TBNA. Five patients (7.69%) had a history of gynecologic malignancy. Two patients had evidence of PET-positive nodes on surveillance scans, which led directly to the examination. Our findings suggest that distant malignancies may cause granulomatous lymphadenitis, through yet undefined mechanisms. As such, patients with evidence of mediastinal lymphadenopathy could benefit from routine sampling and histologic examination to define the pathology in the correct clinical context.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2018 ","pages":"5141575"},"PeriodicalIF":4.3,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/5141575","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36019965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients 囊性纤维化患者重复每日一次妥布霉素疗程后的肾小球和小管肾功能
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2017-01-04 DOI: 10.1155/2017/2602653
F. Stehling, R. Büscher, J. Große-Onnebrink, P. Hoyer, U. Mellies
Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme.
介绍。针对囊性纤维化(CF)患者铜绿假单胞菌肺部感染的抗生素治疗方案通常包括氨基糖苷类抗生素,反复疗程后可能导致慢性肾衰竭。氨基酸尿症是急性氨基糖苷性肾小管功能障碍的早期标志。我们假设尿氨基酸重吸收在重复每日一次妥布霉素治疗后减少。方法。在这项前瞻性横断面研究中,肌酐清除率由Schwartz和Cockcroft-Gault公式估计。采用离子交换色谱法测定46例CF患者的管状氨基酸重吸收,这些CF患者在每日一次给药方案中接受了多个妥布霉素疗程(6.3±10.1(1-57)),10例患者没有接受。结果。使用Cockcroft-Gault方法估计的肌酐清除率在接受妥布霉素治疗的患者中有17/46(37%)轻度降低,在未接受妥布霉素治疗的患者中有5/10(50%)轻度降低,但使用Schwartz方法的患者中没有。与终生妥布霉素疗程无关联。管状氨基酸重吸收不受每日一次妥布霉素疗程量的影响。结论。临床上,少数CF患者的eCCL没有显著减少。然而,慢性小管功能障碍不存在于CF患者反复使用妥布霉素每日一次给药方案。
{"title":"Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients","authors":"F. Stehling, R. Büscher, J. Große-Onnebrink, P. Hoyer, U. Mellies","doi":"10.1155/2017/2602653","DOIUrl":"https://doi.org/10.1155/2017/2602653","url":null,"abstract":"Introduction. Antibiotic treatment regimens against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients often include aminoglycoside antibiotics that may cause chronic renal failure after repeated courses. Aminoaciduria is an early marker of acute aminoglycoside-induced renal tubular dysfunction. We hypothesized that urinary amino acid reabsorption is decreased after repeated once-daily tobramycin therapies. Methods. In this prospective cross-sectional study creatinine clearance was estimated by the Schwartz and the Cockcroft-Gault formula. Tubular amino acid reabsorption was determined by ion exchange chromatography in 46 patients with CF who received multiple tobramycin courses (6.3 ± 10.1 (1–57)) in a once-daily dosing regimen and 10 who did not. Results. Estimated creatinine clearance employing the Cockcroft-Gault was mildly reduced in 17/46 (37%) of the patients who received tobramycin and 5/10 (50%) of the patients who did not but in none using the Schwartz formula. No association with lifetime tobramycin courses was found. Tubular amino acid reabsorption was not influenced by the amount of once-daily tobramycin courses. Conclusion. Clinically not significant reduction of eCCL occurred in a minority of CF patients. However, chronic tubular dysfunction was not present in patients with CF repeatedly treated with tobramycin in the once-daily dosing scheme.","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"237 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2017-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76854103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Role of Transbronchial Lung Cryobiopsies in Diffuse Parenchymal Lung Diseases: Interest of a Sequential Approach. 经支气管肺低温活检在弥漫性肺实质疾病中的作用:序贯方法的兴趣。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2017-01-01 Epub Date: 2017-04-20 DOI: 10.1155/2017/6794343
Benjamin Bondue, Thierry Pieters, Patrick Alexander, Paul De Vuyst, Maria Ruiz Patino, Delphine Hoton, Myriam Remmelink, Dimitri Leduc

Background. Transbronchial lung cryobiopsies (TBLCs) are a promising diagnostic tool in the setting of diffuse parenchymal lung diseases (DPLDs). However, no comparison with surgical lung biopsy (SLB) in the same patient is available. Methods. The diagnostic yield and safety data of TBLCs, as well as the result of SLB performed after TBLCs, were analysed in a multicentric Belgian study. A SLB was performed after TBLCs in absence of a definite pathological diagnosis or if a NSIP pattern was observed without related condition identified following multidisciplinary discussion. Results. Between April 2015 and November 2016, 30 patients were included. Frequent complications included pneumothorax (20%) and bleeding (severe 7%, moderate 33%, and mild 53%). There was no mortality. The overall diagnostic yield was 80%. A SLB was performed in six patients (three without definite histological pattern and three with an NSIP). The surgical biopsy changed the pathological diagnosis into a UIP pattern in five patients and confirmed a NSIP pattern in one patient. Conclusion. TBLCs are useful in the diagnostic work-up of DPLDs avoiding a SLB in 80% of the patients. However, surgical biopsies, performed as a second step after TBLCs because of an indefinite diagnosis or a NSIP pattern, provide additional information supporting the interest of a sequential approach in these patients.

背景。经支气管肺低温活检(TBLCs)是一种很有前途的诊断弥漫性肺实质疾病(DPLDs)的工具。然而,在同一患者中,没有与外科肺活检(SLB)的比较。方法。在比利时的一项多中心研究中,分析了tblc的诊断率和安全性数据,以及tblc后SLB的结果。在没有明确病理诊断的情况下,或者在多学科讨论后没有发现相关疾病的情况下,观察到NSIP模式,则进行SLB。结果。2015年4月至2016年11月,纳入30例患者。常见的并发症包括气胸(20%)和出血(重度7%,中度33%,轻度53%)。没有死亡。总诊断率为80%。6例患者行SLB(3例无明确组织学类型,3例有NSIP)。手术活检将5例患者的病理诊断改变为UIP型,1例患者确认为NSIP型。结论。tblc在dpld的诊断工作中是有用的,在80%的患者中避免了SLB。然而,由于诊断不明确或NSIP模式,手术活检作为TBLCs后的第二步,提供了额外的信息,支持对这些患者采用顺序方法的兴趣。
{"title":"Role of Transbronchial Lung Cryobiopsies in Diffuse Parenchymal Lung Diseases: Interest of a Sequential Approach.","authors":"Benjamin Bondue,&nbsp;Thierry Pieters,&nbsp;Patrick Alexander,&nbsp;Paul De Vuyst,&nbsp;Maria Ruiz Patino,&nbsp;Delphine Hoton,&nbsp;Myriam Remmelink,&nbsp;Dimitri Leduc","doi":"10.1155/2017/6794343","DOIUrl":"https://doi.org/10.1155/2017/6794343","url":null,"abstract":"<p><p><i>Background.</i> Transbronchial lung cryobiopsies (TBLCs) are a promising diagnostic tool in the setting of diffuse parenchymal lung diseases (DPLDs). However, no comparison with surgical lung biopsy (SLB) in the same patient is available. <i>Methods.</i> The diagnostic yield and safety data of TBLCs, as well as the result of SLB performed after TBLCs, were analysed in a multicentric Belgian study. A SLB was performed after TBLCs in absence of a definite pathological diagnosis or if a NSIP pattern was observed without related condition identified following multidisciplinary discussion. <i>Results.</i> Between April 2015 and November 2016, 30 patients were included. Frequent complications included pneumothorax (20%) and bleeding (severe 7%, moderate 33%, and mild 53%). There was no mortality. The overall diagnostic yield was 80%. A SLB was performed in six patients (three without definite histological pattern and three with an NSIP). The surgical biopsy changed the pathological diagnosis into a UIP pattern in five patients and confirmed a NSIP pattern in one patient. <i>Conclusion.</i> TBLCs are useful in the diagnostic work-up of DPLDs avoiding a SLB in 80% of the patients. However, surgical biopsies, performed as a second step after TBLCs because of an indefinite diagnosis or a NSIP pattern, provide additional information supporting the interest of a sequential approach in these patients.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2017 ","pages":"6794343"},"PeriodicalIF":4.3,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/6794343","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35003852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 24
Guiding Inspiratory Flow: Development of the In-Check DIAL G16, a Tool for Improving Inhaler Technique. 引导吸气流动:改进吸入器技术的一种工具-在检DIAL G16的开发。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2017-01-01 Epub Date: 2017-11-16 DOI: 10.1155/2017/1495867
Mark Jeremy Sanders

Portable inhalers are divisible into those that deliver medication by patient triggering (pMDIs: a gentle slow inhalation) and those that use the patient's inspiratory effort as the force for deaggregation and delivery (DPIs: a stronger deeper inspiratory effort). Patient confusion and poor technique are commonplace. The use of training tools has become standard practice, and unique amongst these is an inspiratory flow meter (In-Check) which is able to simulate the resistance characteristics of different inhalers and, thereby, guide the patient to the correct effort. In-Check's origins lie in the 1960s peak expiratory flow meters, the development of the Mini-Wright peak flow meter, and inspiratory flow assessment via the nose during the 1970s-1980s. The current device (In-Check DIAL G16) is the third iteration of the original 1998 training tool, with detailed and ongoing assessments of all common inhaler resistances (including combination and breath-actuated inhaler types) summarised into resistance ranges that are preset within the device. The device works by interpolating one of six ranges with the inspiratory effort. Use of the tool has been shown to be contributory to significant improvements in asthma care and control, and it is being advocated for assessment and training in irreversible lung disease.

便携式吸入器可分为两种,一种是通过患者触发(pmdi:温和缓慢的吸入)给药,另一种是利用患者的吸气力作为解聚和给药的力量(DPIs:更强的吸气力)。病人的困惑和糟糕的技术是司空见惯的。培训工具的使用已成为标准做法,其中独特的是吸气流量计(In-Check),它能够模拟不同吸入器的阻力特性,从而指导患者进行正确的努力。in - check起源于20世纪60年代呼气峰值流量计,Mini-Wright峰值流量计的发展,以及20世纪70 - 80年代通过鼻子进行吸气流量评估。目前的设备(In-Check DIAL G16)是1998年原始培训工具的第三次迭代,对所有常见吸入器阻力(包括组合和呼吸驱动吸入器类型)进行了详细和持续的评估,并将其总结为设备内预设的阻力范围。该装置的工作原理是通过吸气的力度插入六个范围中的一个。该工具的使用已被证明有助于显著改善哮喘护理和控制,并且正在提倡对不可逆肺病进行评估和培训。
{"title":"Guiding Inspiratory Flow: Development of the In-Check DIAL G16, a Tool for Improving Inhaler Technique.","authors":"Mark Jeremy Sanders","doi":"10.1155/2017/1495867","DOIUrl":"https://doi.org/10.1155/2017/1495867","url":null,"abstract":"<p><p>Portable inhalers are divisible into those that deliver medication by patient triggering (pMDIs: a gentle slow inhalation) and those that use the patient's inspiratory effort as the force for deaggregation and delivery (DPIs: a stronger deeper inspiratory effort). Patient confusion and poor technique are commonplace. The use of training tools has become standard practice, and unique amongst these is an inspiratory flow meter (In-Check) which is able to simulate the resistance characteristics of different inhalers and, thereby, guide the patient to the correct effort. In-Check's origins lie in the 1960s peak <i>expiratory</i> flow meters, the development of the Mini-Wright peak flow meter, and inspiratory flow assessment via the nose during the 1970s-1980s. The current device (In-Check DIAL G16) is the third iteration of the original 1998 training tool, with detailed and ongoing assessments of all common inhaler resistances (including combination and breath-actuated inhaler types) summarised into resistance ranges that are preset within the device. The device works by interpolating one of six ranges with the inspiratory effort. Use of the tool has been shown to be contributory to significant improvements in asthma care and control, and it is being advocated for assessment and training in irreversible lung disease.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2017 ","pages":"1495867"},"PeriodicalIF":4.3,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/1495867","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35749047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 53
Tomographic Aspects of Advanced Active Pulmonary Tuberculosis and Evaluation of Sequelae following Treatment. 晚期活动性肺结核的断层扫描和治疗后后遗症的评价。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2017-01-01 Epub Date: 2017-02-05 DOI: 10.1155/2017/9876768
Rafael Barcelos Capone, Domenico Capone, Thiago Mafort, Roberto Mogami, Rosana de Souza Rodrigues, Miriam Menna Barreto, Rogerio Rufino

Objectives. To evaluate tomographic changes in pulmonary tuberculosis (TB), degree of agreement among three radiologists regarding tomographic diagnoses, and sequelae following treatment. Methods. Cross-sectional and descriptive study of 74 TB patients confirmed by sputum culture and chest computed tomography before (CT1) and 6 months after (CT2) drug therapy. Results were performed by three radiologists blinded to clinical and laboratory results. Results. Main findings in CT1 included nodules indicating the presence of a tree-in-bud pattern in 93% of cases, ill-defined nodules in 84% of cases, consolidation in 77% of cases, architectural distortion in 71% of cases, cavitary lesions in 62% of cases, and ground glass opacities in 37% of cases. Airway involvement, characterized by increased thickness and dilatation of the bronchial walls, occurred in 93% of cases. Pleural involvement occurred in 54%. There was an agreement on active TB among the three radiologists in 85% of cases. The results in CT2 indicated the presence of architectural distortion in 91% of cases and cylindrical bronchiectasis in 86%. Conclusions. The study established a tomographic pattern for diagnosis of active TB characterized by the presence of airway nodules, consolidation, architectural distortion, and cavitary lesions, and an almost complete degree of agreement (Kappa) was observed among the radiologists (0.85). CT after treatment assists in defining the cure.

目标。评估肺结核(TB)的断层扫描改变,三位放射科医生对断层扫描诊断的一致程度,以及治疗后的后遗症。方法。74例结核病患者在药物治疗前(CT1)和药物治疗后(CT2) 6个月经痰培养和胸部计算机断层扫描证实的横断面和描述性研究结果由三名对临床和实验室结果不知情的放射科医生执行。结果。CT1的主要表现包括结节,93%的病例表现为树状芽状,84%的病例表现为结节不清,77%的病例表现为实变,71%的病例表现为结构扭曲,62%的病例表现为空洞性病变,37%的病例表现为磨玻璃样混浊。气道受累,以支气管壁厚度增加和扩张为特征,发生在93%的病例中。54%发生胸膜受累。在85%的病例中,三位放射科医生对活动性结核病的诊断是一致的。CT2结果显示91%的病例存在建筑扭曲,86%的病例存在圆柱形支气管扩张。结论。该研究建立了一种以气道结节、实变、结构扭曲和空洞病变为特征的活动性结核病的断层扫描模式,在放射科医生中观察到几乎完全一致的程度(Kappa)(0.85)。治疗后CT有助于确定治愈情况。
{"title":"Tomographic Aspects of Advanced Active Pulmonary Tuberculosis and Evaluation of Sequelae following Treatment.","authors":"Rafael Barcelos Capone,&nbsp;Domenico Capone,&nbsp;Thiago Mafort,&nbsp;Roberto Mogami,&nbsp;Rosana de Souza Rodrigues,&nbsp;Miriam Menna Barreto,&nbsp;Rogerio Rufino","doi":"10.1155/2017/9876768","DOIUrl":"https://doi.org/10.1155/2017/9876768","url":null,"abstract":"<p><p><i>Objectives.</i> To evaluate tomographic changes in pulmonary tuberculosis (TB), degree of agreement among three radiologists regarding tomographic diagnoses, and sequelae following treatment. <i>Methods.</i> Cross-sectional and descriptive study of 74 TB patients confirmed by sputum culture and chest computed tomography before (CT1) and 6 months after (CT2) drug therapy. Results were performed by three radiologists blinded to clinical and laboratory results. <i>Results.</i> Main findings in CT1 included nodules indicating the presence of a tree-in-bud pattern in 93% of cases, ill-defined nodules in 84% of cases, consolidation in 77% of cases, architectural distortion in 71% of cases, cavitary lesions in 62% of cases, and ground glass opacities in 37% of cases. Airway involvement, characterized by increased thickness and dilatation of the bronchial walls, occurred in 93% of cases. Pleural involvement occurred in 54%. There was an agreement on active TB among the three radiologists in 85% of cases. The results in CT2 indicated the presence of architectural distortion in 91% of cases and cylindrical bronchiectasis in 86%. <i>Conclusions.</i> The study established a tomographic pattern for diagnosis of active TB characterized by the presence of airway nodules, consolidation, architectural distortion, and cavitary lesions, and an almost complete degree of agreement (Kappa) was observed among the radiologists (0.85). CT after treatment assists in defining the cure.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2017 ","pages":"9876768"},"PeriodicalIF":4.3,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/9876768","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34784035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Guideline-Based Early Detection of Chronic Obstructive Pulmonary Disease in Eight Danish Municipalities: The TOP-KOM Study. 丹麦八个城市基于指南的慢性阻塞性肺病早期检测:TOP-KOM 研究。
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2017-01-01 Epub Date: 2017-02-20 DOI: 10.1155/2017/7620397
Ulla Borup Hemmingsen, Margit Stycke, Jens Dollerup, Peter Bo Poulsen

Background. Early detection of chronic obstructive pulmonary disease (COPD) and prevention of disease progression are important. Only 40% of COPD cases are diagnosed in Denmark. Recommendations for early case finding have been established. This study investigates early detection of pulmonary obstruction in a Danish municipality setting. Methods. Eight municipalities participated. Citizens fulfilling national case finding recommendations, age ≥35 years, smokers/ex-smokers/relevant occupational exposure, and at least one respiratory symptom, were invited to spirometry. Citizens with indication of pulmonary obstruction, forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) < 0.70, were referred to their general practitioner (GP). Results. 1,499 citizens were examined (53.6% male, mean age 57.2 years). 44.8% were current smokers with 57% planning for smoking cessation. The citizens recorded significant airway symptoms with dyspnea being the most important (71%). The mean FEV1/FVC score was 73.54 (SD 22.84). 456 citizens (30.4%) were found to have indication for pulmonary obstruction and were referred to GP for further diagnosis. Conclusion. Early detection in Danish municipalities proved effective finding nearly 1/3 being pulmonary obstructive. It seems to be of value to have municipalities to perform case finding together with smoking cessation as a primary intervention in COPD management.

背景。早期发现慢性阻塞性肺病(COPD)和预防疾病恶化非常重要。在丹麦,只有 40% 的慢性阻塞性肺病病例得到诊断。有关早期病例发现的建议已经确立。本研究调查了在丹麦城市环境中早期发现肺阻塞的情况。方法。八个城市参与了这项研究。符合国家病例发现建议、年龄≥35 岁、吸烟者/前吸烟者/有相关职业暴露、至少有一种呼吸道症状的市民被邀请进行肺活量测定。有肺部阻塞迹象(一秒钟用力呼气容积(FEV1)/用力肺活量(FVC)< 0.70)的市民将被转诊至全科医生(GP)。结果共有 1,499 名市民接受了检查(53.6% 为男性,平均年龄为 57.2 岁)。44.8%的人目前吸烟,57%的人计划戒烟。市民们都有明显的气道症状,其中以呼吸困难最为严重(71%)。平均 FEV1/FVC 评分为 73.54(标准差 22.84)。456名市民(30.4%)被发现有肺阻塞的迹象,并被转诊至全科医生作进一步诊断。结论事实证明,丹麦城市的早期检测有效地发现了近三分之一的肺阻塞患者。看来,让市政当局将病例发现与戒烟作为慢性阻塞性肺病管理的主要干预措施是有价值的。
{"title":"Guideline-Based Early Detection of Chronic Obstructive Pulmonary Disease in Eight Danish Municipalities: The TOP-KOM Study.","authors":"Ulla Borup Hemmingsen, Margit Stycke, Jens Dollerup, Peter Bo Poulsen","doi":"10.1155/2017/7620397","DOIUrl":"10.1155/2017/7620397","url":null,"abstract":"<p><p><i>Background</i>. Early detection of chronic obstructive pulmonary disease (COPD) and prevention of disease progression are important. Only 40% of COPD cases are diagnosed in Denmark. Recommendations for early case finding have been established. This study investigates early detection of pulmonary obstruction in a Danish municipality setting. <i>Methods</i>. Eight municipalities participated. Citizens fulfilling national case finding recommendations, age ≥35 years, smokers/ex-smokers/relevant occupational exposure, and at least one respiratory symptom, were invited to spirometry. Citizens with indication of pulmonary obstruction, forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC) < 0.70, were referred to their general practitioner (GP). <i>Results</i>. 1,499 citizens were examined (53.6% male, mean age 57.2 years). 44.8% were current smokers with 57% planning for smoking cessation. The citizens recorded significant airway symptoms with dyspnea being the most important (71%). The mean FEV<sub>1</sub>/FVC score was 73.54 (SD 22.84). 456 citizens (30.4%) were found to have indication for pulmonary obstruction and were referred to GP for further diagnosis. <i>Conclusion</i>. Early detection in Danish municipalities proved effective finding nearly 1/3 being pulmonary obstructive. It seems to be of value to have municipalities to perform case finding together with smoking cessation as a primary intervention in COPD management.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"2017 ","pages":"7620397"},"PeriodicalIF":4.3,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34835906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electronic Cigarettes for Curbing the Tobacco-Induced Burden of Noncommunicable Diseases: Evidence Revisited with Emphasis on Challenges in Sub-Saharan Africa 电子烟用于遏制烟草引起的非传染性疾病负担:重新审视证据,重点关注撒哈拉以南非洲的挑战
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2016-12-25 DOI: 10.1155/2016/4894352
J. R. Nansseu, J. Bigna
Introduction. This review examines whether electronic cigarettes (e-cigs) implementation or vulgarization in sub-Saharan Africa (SSA) could be helpful in curtailing the toll of tobacco smoking in the region. Discussion. There are about 1.3 billion smokers worldwide, with nearly 80% of them living in developing countries where the burden of tobacco-related illnesses and deaths is the heaviest. Studies report that e-cigs may facilitate smoking cessation, reduction, or abstinence and may pose only a small fraction of the risks of traditional tobacco cigarettes; e-cigs may also considerably reduce second-hand smoking. Thereby, implementation of e-cig use could help to substantially reduce the burden driven by tobacco smoking in SSA, in a particular context of lack of regulations and control policies towards this threat. However, the evidence is not clear on whether e-cigs are risk-free, especially if used in the long term. Conclusions. On the whole, if e-cigs were to be introduced in SSA, they should be strictly recommended to current and/or ex-smokers as a method to quit smoking or prevent relapse and never-smokers should be strongly encouraged to avoid using these devices. Bans on sales of e-cigs to youngsters should be legislated, e-cig advertisements prohibited, and their usage continuously controlled and monitored.
介绍。本综述探讨了在撒哈拉以南非洲(SSA)实施或普及电子烟(e-cigs)是否有助于减少该地区吸烟的死亡人数。讨论。全世界约有13亿吸烟者,其中近80%生活在与烟草有关的疾病和死亡负担最重的发展中国家。研究报告称,电子烟可能有助于戒烟、减少或戒烟,并且可能只构成传统卷烟风险的一小部分;电子烟也可能大大减少二手烟。因此,在缺乏针对这一威胁的法规和控制政策的特定背景下,实施电子烟使用可以帮助大幅减轻SSA吸烟造成的负担。然而,证据尚不清楚电子烟是否没有风险,特别是如果长期使用的话。结论。总的来说,如果要在SSA引入电子烟,应严格建议当前和/或戒烟者将其作为戒烟或防止复发的方法,并应强烈鼓励从不吸烟者避免使用这些设备。应该立法禁止向青少年销售电子烟,禁止电子烟广告,并持续控制和监测电子烟的使用。
{"title":"Electronic Cigarettes for Curbing the Tobacco-Induced Burden of Noncommunicable Diseases: Evidence Revisited with Emphasis on Challenges in Sub-Saharan Africa","authors":"J. R. Nansseu, J. Bigna","doi":"10.1155/2016/4894352","DOIUrl":"https://doi.org/10.1155/2016/4894352","url":null,"abstract":"Introduction. This review examines whether electronic cigarettes (e-cigs) implementation or vulgarization in sub-Saharan Africa (SSA) could be helpful in curtailing the toll of tobacco smoking in the region. Discussion. There are about 1.3 billion smokers worldwide, with nearly 80% of them living in developing countries where the burden of tobacco-related illnesses and deaths is the heaviest. Studies report that e-cigs may facilitate smoking cessation, reduction, or abstinence and may pose only a small fraction of the risks of traditional tobacco cigarettes; e-cigs may also considerably reduce second-hand smoking. Thereby, implementation of e-cig use could help to substantially reduce the burden driven by tobacco smoking in SSA, in a particular context of lack of regulations and control policies towards this threat. However, the evidence is not clear on whether e-cigs are risk-free, especially if used in the long term. Conclusions. On the whole, if e-cigs were to be introduced in SSA, they should be strictly recommended to current and/or ex-smokers as a method to quit smoking or prevent relapse and never-smokers should be strongly encouraged to avoid using these devices. Bans on sales of e-cigs to youngsters should be legislated, e-cig advertisements prohibited, and their usage continuously controlled and monitored.","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"1 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2016-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83055656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Protease Inhibitors Extracted from Caesalpinia echinata Lam. Affect Kinin Release during Lung Inflammation 棘荆芥蛋白酶抑制剂的提取。影响肺部炎症时激肽的释放
IF 4.3 Q3 RESPIRATORY SYSTEM Pub Date : 2016-12-01 DOI: 10.1155/2016/9425807
Ilana Cruz-Silva, V. A. Nunes, A. J. Gozzo, Priscila Praxedes-Garcia, A. Tanaka, K. Shimamoto, M. Araujo
Inflammation is an essential process in many pulmonary diseases in which kinins are generated by protease action on kininogen, a phenomenon that is blocked by protease inhibitors. We evaluated kinin release in an in vivo lung inflammation model in rats, in the presence or absence of CeKI (C. echinata kallikrein inhibitor), a plasma kallikrein, cathepsin G, and proteinase-3 inhibitor, and rCeEI (recombinant C. echinata elastase inhibitor), which inhibits these proteases and also neutrophil elastase. Wistar rats were intravenously treated with buffer (negative control) or inhibitors and, subsequently, lipopolysaccharide was injected into their lungs. Blood, bronchoalveolar lavage fluid (BALF), and lung tissue were collected. In plasma, kinin release was higher in the LPS-treated animals in comparison to CeKI or rCeEI groups. rCeEI-treated animals presented less kinin than CeKI-treated group. Our data suggest that kinins play a pivotal role in lung inflammation and may be generated by different enzymes; however, neutrophil elastase seems to be the most important in the lung tissue context. These results open perspectives for a better understanding of biological process where neutrophil enzymes participate and indicate these plant inhibitors and their recombinant correlates for therapeutic trials involving pulmonary diseases.
炎症是许多肺部疾病的重要过程,其中激肽是由蛋白酶作用于激肽原产生的,这一现象被蛋白酶抑制剂阻断。我们在大鼠体内肺炎症模型中评估了激肽的释放,在存在或不存在CeKI(紫锥菊激肽抑制剂)、血浆激肽、组织蛋白酶G和蛋白酶3抑制剂以及rCeEI(重组紫锥菊弹性酶抑制剂)的情况下,后者抑制这些蛋白酶和中性粒细胞弹性酶。Wistar大鼠静脉注射缓冲液(阴性对照)或抑制剂,随后将脂多糖注射到肺中。采集血液、支气管肺泡灌洗液(BALF)和肺组织。在血浆中,与CeKI或rCeEI组相比,lps处理动物的激肽释放量更高。与ceki治疗组相比,rceei治疗组小鼠出现的激肽较少。我们的数据表明,激肽在肺部炎症中起关键作用,可能由不同的酶产生;然而,中性粒细胞弹性蛋白酶在肺组织中似乎是最重要的。这些结果为更好地理解中性粒细胞酶参与的生物学过程提供了新的视角,并表明这些植物抑制剂及其重组相关物质与肺部疾病的治疗试验有关。
{"title":"Protease Inhibitors Extracted from Caesalpinia echinata Lam. Affect Kinin Release during Lung Inflammation","authors":"Ilana Cruz-Silva, V. A. Nunes, A. J. Gozzo, Priscila Praxedes-Garcia, A. Tanaka, K. Shimamoto, M. Araujo","doi":"10.1155/2016/9425807","DOIUrl":"https://doi.org/10.1155/2016/9425807","url":null,"abstract":"Inflammation is an essential process in many pulmonary diseases in which kinins are generated by protease action on kininogen, a phenomenon that is blocked by protease inhibitors. We evaluated kinin release in an in vivo lung inflammation model in rats, in the presence or absence of CeKI (C. echinata kallikrein inhibitor), a plasma kallikrein, cathepsin G, and proteinase-3 inhibitor, and rCeEI (recombinant C. echinata elastase inhibitor), which inhibits these proteases and also neutrophil elastase. Wistar rats were intravenously treated with buffer (negative control) or inhibitors and, subsequently, lipopolysaccharide was injected into their lungs. Blood, bronchoalveolar lavage fluid (BALF), and lung tissue were collected. In plasma, kinin release was higher in the LPS-treated animals in comparison to CeKI or rCeEI groups. rCeEI-treated animals presented less kinin than CeKI-treated group. Our data suggest that kinins play a pivotal role in lung inflammation and may be generated by different enzymes; however, neutrophil elastase seems to be the most important in the lung tissue context. These results open perspectives for a better understanding of biological process where neutrophil enzymes participate and indicate these plant inhibitors and their recombinant correlates for therapeutic trials involving pulmonary diseases.","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":"42 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89585721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Pulmonary Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1